Biotech Values

[The Rainmaker]

Glaxo went to a meeting with FOLD in May reviewed all the trial data FOLD had to date and Glaxo left the meeting and upped their stake in FOLD paying well over $6 per share.011 which is their big trial, that Data is going to be unblinded sometime in next 30 days give or take a few..All 66 patients in the trial signed back up for another 6 months and Folds drug is all they have taken for the past 6 months....the drug appears to be working on the patients.Fabry is a very painful disease, there's ust no way these people could have made it this long just taking FOLD's drug if it was not effective imho.